A trial into lung cancer drug ASA404 whas been halted in the late stage due to its lack of effectiveness.
There was deemed to be little chance of the drug showing it could increase survival rates for people who had previously untreated significant cell lung cancer. The news was a big setback in the drug pipeline for British cancer specialist Antisoma.
The drug was one of two in final Phase III trials for the company, which was developing ASA404 with Swiss drugmaker Novartis. The other key product was blood cancer treatment AS1413.
Antisoma Chief Executive Glyn Edwards said: “We are disappointed by the outcome of the ATTRACT-1 study, especially given the very encouraging Phase II data reported in the same setting.
“We are now focused on delivering Phase III results for our other late-stage product, AS1413.”
Copyright Press Association 2010